Trial watch: Bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma Review

   

Authors:	Cassanello, G.; Luna de Abia, A.; Falchi, L.
Review Title:	Trial watch: Bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
Abstract:	Immunotherapy has shaped the treatment approach to diffuse large B-cell lymphoma (DLBCL), with rituximab leading to remarkable improvements in outcomes for both relapsed and treatment-naïve patients. Recently, groundbreaking immunotherapies like chimeric antigen receptor T-cells have entered the treatment arena for relapsed/refractory (R/R) DLBCL and gained regulatory approval in several countries. The concept of harnessing a patient’s own T-cells to combat cancer has been further explored through the development of bispecific antibodies (BsAbs), a class of engineered antibody products designed to simultaneously target two different antigens. These novel drugs have demonstrated impressive single-agent activity and manageable toxicity in patients with heavily pretreated B-cell non-Hodgkin lymphoma. In this review, we provide an up-to-date overview of recently completed or ongoing BsAbs trials in patients with R/R DLBCL, including single-agent results, emerging combination data, and novel constructs. © 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
Keywords:	overall survival; neutropenia; diarrhea; drug withdrawal; hypophosphatemia; gemcitabine; cytarabine; rituximab; drug megadose; neurotoxicity; carboplatin; progression free survival; thrombocytopenia; relapse; dexamethasone; continuous infusion; dizziness; insomnia; cd20 antigen; immunotherapy; immunoglobulin g; drug combination; drug clearance; lymphoma, large b-cell, diffuse; drug half life; drug therapy; oxaliplatin; adverse drug reaction; cd19 antigen; antibody dependent cellular cytotoxicity; non-hodgkin lymphoma; cd22 antigen; dlbcl; clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); major histocompatibility antigen; cytokine release syndrome; diffuse large b cell lymphoma; antibodies, bispecific; bispecific antibody; cd37 antigen; blinatumomab; humans; human; article; bispecific antibodies; polatuzumab vedotin; cemiplimab; cd79b antigen; tafasitamab; mosunetuzumab; odronextamab; epcoritamab; glofitamab; emfizatamab; imvotamab; loncastuximab; maplirpacept; plamotamab; tiragolumab
Journal Title:	OncoImmunology
Volume:	13
Issue:	1
ISSN:	2162-4011
Publisher:	Landes Bioscience
Date Published:	2024-01-01
Start Page:	2321648
Language:	English
DOI:	10.1080/2162402x.2024.2321648
PUBMED:	38445082
PROVIDER:	scopus
PMCID:	PMC10913711
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187185744&doi=10.1080%2f2162402X.2024.2321648&partnerID=40&md5=4cbfdb92304267a8f062a046c08bda15
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/214724